Comparing the efficacy and safety of extended vs standard dosing of ocrelizumab in MS: A systemic review and meta-analysis.

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 8fe98f6c3c77eb22-LAX IP: 116.62.10.13 UTC time: 2025-01-08T04:49:18+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4